Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lophius Biosciences Performs Successful Clinical Validation for T-Track® CMV/EBV Test Systems

Published: Thursday, April 26, 2012
Last Updated: Wednesday, April 25, 2012
Bookmark and Share
Both systems aim to increase transplantation outcome and reduce negative therapeutic effects.

Lophius Biosciences has announced the successful completion of a prospective multicenter clinical validation study for its T-Track® CMV/EBV tests.

In cooperation with four dialysis centers in Germany (Regensburg, Mannheim, Straubing and Landshut) the ability of both T-Track® CMV/EBV tests with respect to determination of functional effector cells of cell-mediated immunity was successfully examined during 4th quarter 2011 in a cohort of > 120 hemodialysis patients.

Using standard statistical analysis tools, the clinical sensitivities were 100% for T-Track® CMV and 97% for T-Track® EBV in this cohort.

Based on the study results Lophius Biosciences was able to develop a novel simple biostatistical method for T-cell based tests, which should allow comparative analysis between different patient groups in the future.

This is a key prerequisite for the use of both T-Track® CMV/EBV tests for a routine immune monitoring. Using this novel tool, clinical sensitivities were 88% for T-Track® CMV and 86% for T-Track® EBV.

“We were very impressed with the high clinical sensitivities for both T-Track® CMV and T-Track ® EBV Tests“, said Prof. Dr. Bernhard Banas, Department Head of Nephrology und Transplantation Center of the University Hospital Regensburg.

Prof. Banas continued, “In connection with its high degree of standardization, both test systems may be key for a personalized therapy in transplantation medicine, with the aim to increase transplantation outcome and reduce negative therapeutic effects”.

“We are delighted that we were able as part of the validation study to develop an analysis tool for the first time that may set the basis for a standardized measurement of cell-mediated immune response. This should allow a user-friendly monitoring of the immune status of immune compromized patients e.g. after transplantation, but also in other indications” added PD Dr. Ludwig Deml, CSO of Lophius Biosciences.

Dr. Michael Lutz, CEO of Lophius Biosciences, said: “The successful completion of both test developments for both T-Track® CMV and T-Track® EBV tests in a short timeframe underpins the high innovative potential of our proprietary technology platform. This could set the basis for novel T-cell based diagnostic systems in areas with high medical need”.

Lophius Biosciences will present the study results at the world biggest transplantation conference (TTS) in Berlin in July 2012.

Moreover, the company aims to publish the study results as quickly as possible in a leading scientific journal.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lophius Biosciences Appoints Dr. Robert Phelps as Director Business Operations
Dr. Phelps has longstanding experience in business development and licensing.
Wednesday, December 04, 2013
Lophius Biosciences Joins NEU² Program
Company receives substantial grant funding for the diagnosis and monitoring of multiple sclerosis.
Wednesday, June 19, 2013
Lophius Biosciences Closes Financing Round and Expands Management Board
Lophius Biosciences announces the closing of a further financing round with Prof. Dr Ralf Wagner been appointed as Managing Director.
Tuesday, January 22, 2013
Lophius Biosciences Concludes TB Detection Trials
Company achieves first clinical Proof of Principle for T-Track® TB for detection of active tuberculosis and receives research funding.
Thursday, November 08, 2012
Lophius Biosciences Completes Necessary Regulatory Milestones with EN ISO 13485 Certification
Company has received CE-marking for its T-Track® CMV and T-Track® EBV tests.
Friday, June 01, 2012
Lophius Biosciences Closes Additional Financing Round with Current Investors Totaling 1.4 Million EUR
Financial investors such as S-Refit, High-Tech Gründerfonds and Bayernkapital participated in this financing round.
Tuesday, July 19, 2011
Lophius Biosciences Expands its Management Team and Prepares for Market Entry at the Beginning of 2012
The team is completed by Dr. Zanker from MedicalDevice+, an experienced expert in the field of regulatory affairs for diagnostic products.
Tuesday, July 12, 2011
Scientific News
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
Newborn Screening Test Developed For Rare, Deadly Neurological Disorder
Scientists have developed a new dried blood spot screening test for Niemann-Pick type C, with goal to speed diagnosis and treatment.
New Autism Blood Biomarker Identified
Researchers at UT Southwestern Medical Center have identified a blood biomarker that may aid in earlier diagnosis of children with autism spectrum disorder, or ASD.
Autism, Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Five New Breast Cancer Genes Found
Discovery of mutations paves the way for personalised treatment of breast cancer.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Magnetic Nanoparticles May Reveal Early Traces Of Cancer
Rice University students’ computer program aids MD Anderson diagnostic initiative .
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!